DOPAMINE HYDROCHLORIDE This drug must be guardrailed

Trade Name	Sterile Dopamine Concentrate 200mg/5mL (Martindale)			
Class	Catecholamine. Precursor of noradrenaline.			
Mechanism of Action	Increases blood pressure by increasing systemic vascular resistance by alpha-adrenergic effects. Variable effects on cardiac output. Renal vasodilatation may occur in doses between 2.5 and 7.5 micrograms/kg/min, however this is controversial in neonates.			
	Drug effects are dose dependent:			
	Low dose: 2-5 microgram/kg/minute. Little effect seen on heart rate or cardiac output. Increased urine output.			
	Middle dose: 5-15 microgram/kg/minute. Increase in cardiac contractility and output results in increased blood flow and heart rate.			
	High dose: 15 microgram/kg/minute. Alpha adrenergic effects begin to dominate with increased systemic and pulmonary vascular resistance and decrease in perfusion.			
Indications	Hypotension			
Contraindications	Known hypersensitivity to dopamine or sodium metabisulfite. High doses in Persistent Pulmonary Hypertension. Tachyarrhythmias. (Use with caution in patients with a family history of asthma)			
Supplied As	200mg/5mL Dopamine hydrochloride			
Dilution	See dopamine infusion sheet Take (30 x wt(kg) in mg ÷ 40) and make up to 50mL with normal saline, 5% or 10% dextrose without heparin 1 mL/hr = 10 microgram/kg/min			
	** Max concentration 3.2mg/mL - this will be exceeded in babies >5kg and the infusion will need to be made half strength . Note that if the infusion is made "double strength" it will exceed the max. concentration allowed if weight is >2.5kg			
Dosage	5-20 microgram/kg/minute.			
Must chart guardrail and use Alaris pump	Start at 5 microgram/kg/minute and titrate according to response in blood pressure.			
Guardrails	Concentration: Min – 0.18mg/mL Max – 3.2mg/mL Soft Min: 2 microgram/kg/min Hard Max: 20microgram/kg/min Soft Max: 15 microgram/kg/min Default: 5 microgram/kg/min			
Interval	Continuous iv infusion			

Dopamine

Administration	Continuous iv infusion. Need to make up infusion, place in syringe driver and use purge until solution is flowing prior to connecting to baby (or it may take up to an hour to reach the baby's circulation).	
Compatible With	 5 % & 10% Dextrose, 0.9% sodium chloride, dobutamine. Lactated Ringers. TPN Lipid Y site: Adrenaline, alprostadil, aminophylline, amiodarone, aztreonam, caffeine citrate, calcium chloride, caspofungin, cefotaxime, cefoxitin, ceftazidime, chloramphenicol, dobutamine, famotidine, fentanyl, fluconazole, flumazenil, gentamicin, heparin, hydrocortisone succinate, ibuprofen lysine, lidocaine, linezolid, lorazepam, meropenem, metronidazole, midazolam, milrinone, morphine, , nitroglycerin, nitroprusside, pancuronium bromide, piperacillin/tazobactam, potassium chloride, propofol, ranitidine, tobramycin, vecuronium, and zidovudine. Acyclovir, amphotericin B, benzylpenicillin, furosemide, indometacin, sodium bicarbonate. Insulin – data from higher concentrations than we use for both 	
	infusions. We have used this without detectable problems for some years. If concerned change to dobutamine which is compatible at any concentration	
Monitoring	Continuous heart rate, ECG and intra-arterial blood pressure preferably. Urine output, peripheral perfusion. If peripheral iv, monitor iv site closely.	
Stability	Single use vial.	
	Do not use if discoloured (pink, yellow or brown)	
	Continuous infusions must be changed after 24 hours	
Storage	Below 30°C. Protect from light.	
Adverse Reactions	Tachycardia and arrhythmias. May increase pulmonary artery pressure. Reversible suppression of prolactin and thyrotropin secretion. Iv infiltration may cause tissue ischaemia, necrosis and sloughing.	
	In combination with Phenytoin hypotension, bradycardia may occur	
Metabolism	Very short half-life. Steady state in 5-10 minutes. Metabolised in liver and excreted in urine.	
Comments	Correct hypovolaemia first	
	Doses above 15 microgram/kg/min are associated with increasing vasoconstriction. Assess cardiac function / contractility may support adding in dobutamine which is more effective in this situation.	
References	 NZHPA notes on injectable drugs 5th Edition Trissel Handbook on Injectable Drugs 10th Edition Neofax 2001 Medicines for Children RCPCH. Arch Dis Child 1993; 69: 59-63 	

Updated By	P Schmidt, B Robertshawe B Robertshawe, A Lynn A Lynn, B Robertshawe	February 2005 September 2009 June 2012 (re-order profile), May 2013 max. conc
	A Lynn A Lynn, M Wallenstein, B Ro	Aug 2015 guardrail update bertshawe December 2020